Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16393 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Tarita Murray-Thomas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London. Hauptthemen laut MEDLINE: Liraglutide, Obesity, Anti-Obesity Agents, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
Aims
To assess real‐world use of Saxenda® (liraglutide 3.0 mg) and off‐label use of Victoza® (liraglutide 1.2 mg/1.8 mg) for weight management and Saxenda® posology in the United Kingdom. Their similar doses and formulation pose a risk of inadvertent use due to their use for different indications. Materials and Methods This retrospective, non‐interventional drug utilization cohort study (DUS), based on anonymized patient data from the Clinical Practice Research Datalink databases (CPRD Aurum, GOLD), included adult liraglutide initiators without prior prescription 12 months before the index date. Descriptive statistics were used to characterize Saxenda® and Victoza® user demographics and drug utilization.
Results
Totally 604 Saxenda® and 4853 Victoza® patients were included. Approximately half of the Saxenda® initiators (Si's) ( N = 306) had available body weight, of which 96.4% initiated treatment according to the weight loss indication. Si's were more likely female than Victoza® initiators (Vi's) (86.4% vs. 52.1%), younger (mean age ± SD: 46.5 ± 11.7 years) versus (57.5 ± 12.0 years) and with shorter duration of follow‐up observation (18.8 ± 13.9 months) versus (32.9 ± 15.9 months). N < 5 of 16 patients with 24‐weeks body mass index (BMI) data did not adhere to the Saxenda® stopping rule. N < 5 of 92 patients with valid dose used Victoza® outside the diabetes indication.
Conclusions
This DUS provides descriptive data for initiators of liraglutide in the initial 5‐year period following the launch of Saxenda® in the United Kingdom. Real‐world use of Saxenda® and Victoza® raised no new safety concerns. Where assessment was possible, Saxenda® and Victoza® were mostly prescribed by physicians according to their approved indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London.
- Novo Nordisk A/S, Søborg, Denmark.
- Novo Nordisk A/S, Global Patient Safety, Søborg, Denmark.
ORCID-Profile: Atheline Major-Pedersen
Förderung
- Novo Nordisk
Zitieren
APA
Murray-Thomas, T., Dcruz, J. M., Harder-Lauridsen, N. M., Olsen, A. H., Williams, R., & Major-Pedersen, A. (2025). Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16393
Vancouver
Murray-Thomas T, Dcruz JM, Harder-Lauridsen NM, Olsen AH, Williams R, Major-Pedersen A. Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16393
BibTeX
@article{MurrayThomas2025,
author = {Murray-Thomas, Tarita and Dcruz, John M and Harder-Lauridsen, Nina M and Olsen, Anne H and Williams, Rachael and Major-Pedersen, Atheline},
title = {Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16393}
}
EUVIMED